Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm

Yasuhiro Nagate; Aya Nakaya; Ren Kamimura; Yumiko Hirose; Satoshi Nojima; Jiro Fujita; Eiji Kiyohara; Hirohiko Shibayama

doi:10.2169/internalmedicine.0318-22

CASE REPORTS

Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm

Yasuhiro Nagate, Aya Nakaya, Ren Kamimura, Yumiko Hirose, Satoshi Nojima, Jiro Fujita, Eiji Kiyohara, Hirohiko Shibayama

Author information

Yasuhiro Nagate
Department of Hematology, National Hospital Organization Osaka National Hospital, Japan
Aya Nakaya
Department of Hematology, National Hospital Organization Osaka National Hospital, Japan
Ren Kamimura
Department of Hematology, National Hospital Organization Osaka National Hospital, Japan
Yumiko Hirose
Department of Central Laboratory and Surgical Pathology, National Hospital Organization Osaka National Hospital, Japan
Satoshi Nojima
Department of Pathology, Osaka University Graduate School of Medicine, Japan
Jiro Fujita
Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan
Eiji Kiyohara
Department of Dermatology, Osaka University Graduate School of Medicine, Japan
Hirohiko Shibayama
Department of Hematology, National Hospital Organization Osaka National Hospital, Japan

Keywords: venetoclax, azacytidine, blastic plasmacytoid dendritic cell neoplasm (BPDCN), elderly, first-line

JOURNAL OPEN ACCESS

2023 Volume 62 Issue 17 Pages 2547-2551

DOI https://doi.org/10.2169/internalmedicine.0318-22

Details

Abstract

An 84-year-old Japanese man was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). We administered combination therapy using venetoclax and azacytidine. We observed neutropenia (Grade 4), thrombocytopenia (Grade 2), and stomatitis (Grade 3). After six cycles of treatment, the BPDCN abnormal cells in the bone marrow specimen almost disappeared, and atypical cells were not detected in a skin biopsy. We propose venetoclax combined with azacytidine as a useful treatment approach in elderly patients, although clinicians should be mindful that therapeutic modifications may be essential to minimize and/or avoid adverse events.

Corresponding author

Register with J-STAGE for free!